Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Prostatic Neoplasms

Adenocarcinoma

Stomach Neoplasms

Breast Neoplasms

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Stomach Cancer

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Docetaxel

Histone Deacetylase Inhibitors

Mocetinostat

Tubulin Modulators

Antimitotic Agents

Enzyme Inhibitors

In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).

Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.

In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.

In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.

There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks.

MGCD0103 & Docetaxel

Gregory Reid, MSc, MBA

The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel. This is a Phase 1 study that will look at different doses of MGCD0103 given along with docetaxel in order to better understand the effects (positive and negative) of this combination on the subject's body and disease.

The study would like to find the following information:

* How long MGCD0103 and docetaxel stay in the subject's body;
* What effects, good and/or bad, MGCD0103 and docetaxel have on the subject and on his/her cancer; and
* If the genetic and chemical make-up of the subject's blood cells and tumor cells play a role in how you respond or do not respond to MGCD0103 and docetaxel.

This Phase 1 study will evaluate escalating doses of orally administered MGCD0103 in combination with two fixed doses (60 mg/m2 and 75 mg/m2) of IV docetaxel. In the US, docetaxel is recommended at these or even higher doses (up to 100 mg/m2), both as a single agent or in combination with other cytotoxic drugs (e.g., cisplatin, doxorubicin, cyclophosphamide, and 5-fluorouracil), for the treatment of NSCLC, prostate cancer, gastric adenocarcinoma, and head and neck cancer. In Japan, 60 mg/m2 IV docetaxel is the approved dose for the treatment of breast cancer.

MGCD0103 belongs to the class of more selective, less globally cytotoxic agents being investigated for treatment of cancers today, and may offer a lesser and/or non-overlapping toxicity profile than the cytotoxic agents with which docetaxel is currently combined. MGCD0103 doses ranging from 50 to 135 mg have been administered in combination with the approved regimen of azacitidine (Vidaza®) (75 mg/m2/day for 5 days every 4 weeks) to patients with high-risk MDS and AML. A 50 mg dose of MGCD0103 has been administered in combination with the approved regimen of gemcitabine (1000 mg/m2 once weekly for 3 consecutive weeks of each 4-week cycle) to patients with advanced solid tumors; higher doses of MGCD0103 will soon be evaluated in that trial.

Given the above, the proposed starting dose of 60 mg/m2 IV docetaxel and 50 mg MGCD0103 is considered appropriately safe for initial investigation of this combination. Based on the results observed in Part 1, the study may also evaluate 75 mg/m2 IV docetaxel and escalating doses of orally administered MGCD0103 in Part 2 in order to determine whether this dosing regimen is safe and would also warrant further investigation.

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere®) in Subjects With Advanced Solid Malignancies

Mirati Therapeutics Inc.

Gregory Reid, Executive Director, Clinical Development

Spots Global Cancer Trial Database for mgcd0103 & docetaxel